A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the ...

Doctors are looking to recruit more people for the trial, which they say could one day be given as a single one-off treatment ...

Multiple sclerosis (MS) is a chronic, inflammatory autoimmune disease that affects the central nervous system (the brain and spinal cord). In MS, the immune system attacks the protective covering ...

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

Tyruko will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. Polpharma Biologics S.A., operating under the Rezon Bio brand and ...

CHERRY HILL, N.J., Aug. 16, 2022 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is proud to announce the launch of the Ultimate MS Treatment Guide – a unique and comprehensive ...

It's a disease hidden in plain sight. Multiple Sclerosis (MS) impacts about 1 in every 400 people, according to the Multiple Sclerosis Clinic at Riverside Regional Medical Center. That means about ...

Scientists believe that targeting the Epstein-Barr virus, which commonly causes glandular fever, could also offer a new treatment pathway for MS.

There’s a spring in former Carson High School teacher Phil Brady’s step now that he doesn’t have to rely on his wheelchair ...